Last reviewed · How we verify
HSK21542-120μg
At a glance
| Generic name | HSK21542-120μg |
|---|---|
| Sponsor | Sichuan Provincial People's Hospital |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in PONV (NA)
- An Economic Study of HSK21542 Injection for Prevention of Postoperative Nausea and Vomiting (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HSK21542-120μg CI brief — competitive landscape report
- HSK21542-120μg updates RSS · CI watch RSS
- Sichuan Provincial People's Hospital portfolio CI